2023-08-29 07:14:31 ET
More on Halozyme, Roche, etc.
- Halozyme Therapeutics, Inc. ( HALO ) Q2 2023 Earnings Call Transcript
- Roche: FX Drug But Positive Outlook
- Roche Holding AG ( OTCQX:RHHBY ) Q2 2023 Earnings Call Transcript
- Halozyme: Inflection Point With argenx's Vyvgart SC Approval (Reiterating Buy)
- Halozyme Therapeutics: Pharma With Growing Royalty Revenue And Product Income
- Roche sends anti-TIGIT developers higher after cancer drug data (update)
- Halozyme Therapeutics Non-GAAP EPS of $0.74 beats by $0.10, revenue of $221.04M beats by $21.09M
- Roche, Alnylam in pact for blood pressure candidate
- Roche pulls thyroid cancer indication for Gavreto
For further details see:
Roche granted U.K. approval for subcutaneous Tecentriq